New HIV diagnoses rose by 31% in the EU/EEA in 2022, with migrants accounting for 49% of cases. Ukrainian refugees made up a significant proportion of new diagnoses, with women disproportionately affected. The increase highlights the need for tailored early testing and treatment approaches to address this growing public health threat.
Scientists identify a link between HIV's gp120 protein and chronic inflammation, leading to premature aging and comorbidities. A clinical trial aims to test the effect of Fostemsavir on reducing cardiovascular diseases and improving quality of life for women living with HIV.
A new study by Rutgers University found that Latino sexual minority men who experience racial and ethnic prejudice are more likely to delay HIV testing, complicating efforts to end the over 40-year epidemic. The researchers suggest that everyday discrimination may be a barrier to testing frequency.
Researchers used simulation modeling to find that achieving equity-centered goals can help reduce racial inequities in life expectancy among black and white men who have sex with men. By allocating resources to develop effective equity-centered interventions, health disparities can be comprehensively addressed.
A study of over 2,300 patients found that HIV-1 neutralizing antibody response decreases over time but highly potent broadly neutralizing antibodies remain detectable. This finding suggests a possible permanent vaccine response and is an important step toward developing an effective HIV-1 vaccine.
A new study by UCSF researchers found that the COVID-19 pandemic slowed progress on reducing HIV blood levels and worsened outcomes for certain groups, particularly Black patients and people who inject illicit drugs. The study tracked data from 17,999 participants across eight large HIV clinics in the US.
Researchers found large reservoirs of proviruses with mutations that help them evade detection, leading to low levels of residual viremia in individuals with HIV. Altered gene expression patterns also contributed to dampened immune responses and increased survival of infected cells.
Researchers created a blood-based test to detect both diseases, measure viral and bacterial loads, and track treatment progress. The test aims to improve patient outcomes by catching immune reconstitution inflammatory syndrome (IRIS) earlier.
Experts call for urgent measures to address discrimination against patients fleeing war or conflict zones, those with serious mental illnesses, and frail elderly patients. Guidelines for treating advanced breast cancer should prioritize patient preferences and involve multidisciplinary care teams.
A new study reveals that CD8+ T cells control HIV infection by both cytolytic effects and non-cytolytic suppression of virus production. The research team used computer modeling and experiments with macaques to understand the immune system's mechanism in controlling HIV infections.
A new study finds that a generic daily HIV prevention pill could reduce new HIV acquisitions by 37% over 10 years, saving $5,000 per person compared to annual screening. Generic PrEP is more cost-saving than current CDC-recommended annual screening in this population.
Scientists have discovered a TB vaccination strategy that prevents lung infection in monkeys infected with SIV, despite the vaccine being contraindicated for people living with HIV. The results show promise for protecting people with HIV against TB, which is the leading cause of death among them.
A new study by Northwestern University found that syphilis rates are nearly twice as high among transgender women and Black gay and bisexual men compared to white gay men. The study suggests that preventing and treating syphilis requires outreach to key populations, particularly those from communities of color.
A study found that only 3 out of 22 African countries with high TB/HIV burden have no national policy on LF-LAM test implementation. Main barriers include lack of funding and training, despite the test being less expensive than other diagnostic tests.
A large public health survey in rural South Africa found that approximately half of people living with HIV, diabetes or hypertension have unmet health needs. The study's novel framework quantifies met and unmet health needs for individuals living with infectious and non-communicable diseases.
A new study by UConn researchers found that patients overwhelmingly prefer the traditional daily oral PrEP pill over newer forms, citing its efficacy and minimal side effects as key factors. The study highlights the importance of addressing socioeconomic disparities to ensure equitable access to these life-saving technologies.
Researchers at Johns Hopkins University have developed a new injectable solution that self-assembles into a gel, releasing lamivudine for up to 42 days with nearly no side effects. This hydrogel could help manage HIV by reducing dosing frequencies and improving treatment adherence.
A mixed methods study of 53,246 patients and 56 clinicians found that gay and lesbian patients, cisgender women, and doctors' sociodemographics are linked to higher odds of documented sexual history. Conversely, older patients, long-term relationships, and non-English primary languages are associated with lower odds.
A new Canadian guideline aims to promote health equity among marginalized groups by providing 16 preventive care recommendations. The guidelines focus on removing barriers to healthcare, prioritizing people from disadvantaged groups, and improving access to essential screenings and interventions.
A large international study led by Danish researchers may have brought us closer to a cure for HIV. The study found that patients who received monoclonal antibodies before pausing their regular treatment experienced a period of virus suppression, and some even saw their immune system partially or completely suppress the virus.
Researchers found that a subset of HIV-infected cells produce viral RNA and proteins during anti-retroviral therapy, which may impact patients' immune responses. The study suggests that these non-functional viral pieces can stimulate an immune response, potentially leading to inflammation and negative consequences for treated individuals.
A Canadian research team has identified the locations of HIV reservoirs in the body, revealing that they are concentrated in the spleen and lymph nodes. The discovery provides a potential window of opportunity for targeting these reservoirs with future therapies.
Research from Boston Medical Center found that providing pragmatic support improved treatment outcomes for people with HIV who inject drugs in St. Petersburg, Russia. The odds of achieving viral load suppression at 12 months were 3 times higher for participants randomized to the intervention group.
Researchers have discovered a blood cancer drug that can kill 'silent' HIV cells and delay reinfections. This breakthrough could lead to a future cure for the disease, which affects an estimated 39 million people worldwide.
The five-year grant will help create a multinational research partnership to gather data on prevention and treatment strategies for cancers caused by HPV and Epstein-Barr viruses among this population. Cancer is the leading cause of death among people living with HIV, with poorer treatment outcomes.
A novel CRISPR-based gene-editing treatment, EBT-001, effectively removes SIV from the genomes of non-human primates without off-target effects. The study's findings support the development of a cure for HIV/AIDS in humans and pave the way for ongoing clinical trials.
Researchers have identified a family of broadly neutralizing antibodies targeting the HIV-1 envelope protein, which may contribute to long-term remission from infection. These antibodies were found to induce the elimination of infected cells and impose a selective pressure on the virus, paving the way for new therapeutic approaches.
Researchers found a novel region in the genome associated with spontaneous control of HIV in populations of African ancestries. CHD1L, a protein involved in DNA repair, shows genetic variation specific to these populations and limits HIV replication in white blood cells.
A genetic variant has been identified that may explain why some people of African ancestry have naturally lower viral loads of HIV, reducing their risk of transmission and slowing disease progression. This discovery could lead to the development of new treatments for those living with HIV.
A new drug formulation designed for treating children with HIV has shown safety, tolerability, and effectiveness in a study published in The Lancet HIV. The formulation contains three medications and was found to suppress HIV levels below 200 copies/mL in 98% of participants.
A study at Johns Hopkins Medicine found that people living with HIV who donate a kidney to others with HIV have a low risk of developing end-stage kidney disease or other kidney problems. The study, which monitored three donors for two to four years post-transplant, bolsters support for living donations from people with HIV.
A new study found that more than one-third of New England colleges and universities do not offer PrEP, a medication that reduces HIV incidence by over 90%. The lack of access hinders HIV prevention efforts among young gay, bisexual, and other men who have sex with men, who account for 80% of new HIV infections among youth ages 13–24.
Researchers have found that gut health is the main determinant of systemic inflammation and disease progression in HIV. By targeting the root cause of problems, therapies may be able to slow the progression of the virus by preserving gut integrity.
Researchers at Salk Institute discovered molecular mechanisms of HIV drug-resistance to Dolutegravir, a breakthrough that could lead to the development of new HIV therapeutics. The study revealed how changes in integrase protein structure can lead to resistance and how another compound, 4d, may overcome this resistance.
A Swiss patient has achieved 20 months of HIV remission after a bone marrow transplant performed as part of cancer treatment. The patient's cells remained HIV-permissive despite the absence of a protective mutation, yet the virus was still undetectable after antiretroviral therapy was discontinued.
A recent study led by Professor Simona Stäger identified a molecular imprint that predisposes memory CD4+ T lymphocytes to cell death in people living with HIV. The discovery could have implications for other chronic infectious diseases and may lead to the development of new therapeutic approaches.
Researchers at Johns Hopkins Medicine have identified a new target for treating HIV infection by blocking the neutral sphingomyelinase-2 (nSMase2) enzyme. Inhibiting this enzyme can prevent HIV replication and kill infected cells, offering a promising therapeutic approach.
Researchers from the University of Copenhagen have solved the mystery of how the Hepatitis C virus evades the human immune system. The virus uses a molecule called FAD as a 'mask', cloaking itself in a form that is already present in cells, making it invisible to the immune system.
A recent study found that international migrants in Australia are at increased risk of HIV infection due to reduced access to PrEP, a highly effective prevention measure. The study identified multiple barriers, including lack of awareness, low risk perception, and provider discrimination, which hinder their ability to access PrEP.
A new study found that three million children and adolescents die from infectious diseases every year, with the greatest impact on low- and middle-income countries. The research highlights the need for policy change and funding to address this unmet health need among older children and adolescents.
A study of commercially insured adults with chronic noncancer pain found that state medical cannabis laws did not lead to a reduction in the use of opioid or nonopioid pain treatments. The researchers also suggested slow implementation and reluctance among healthcare leaders may have contributed to these findings.
A new study found consistently high TB case rates among incarcerated people, but low detection rates. Nearly half of TB cases were not detected, highlighting the need for increased efforts to reduce TB spread in prisons.
A daily dose of 500 mg propolis improved immunity, reduced free radicals, and attenuated chronic inflammation in asymptomatic HIV patients. The study showed a significant reduction in plasma levels of malondialdehyde and an increase in total antioxidant capacity.
Researchers aim to identify best practices for increasing viral suppression in low-income populations with HIV. They will examine state AIDS Drug Assistance Programs to understand disparities in care and outcomes.
A Rensselaer Polytechnic Institute researcher used high hydrostatic pressure to examine conformational dynamics of human tRNA, finding excited states that play a role in both normal function and HIV infection. The study suggests new insights into RNA function and potential targets for therapeutics.
African countries have made significant progress in increasing their share of global HIV research output, rising from 5.1% in 1986 to 31.3% between 1986 and 2020. Despite this growth, the continent still produces relatively low amounts of HIV research compared to its high burden of infections.
A new molecular compound has been identified that can activate latent HIV-1 in cells, showing promise for HIV treatments. Researchers found that this compound, YSE028, can reactivate latently infected cells and induce cell death, potentially leading to a complete cure for HIV.
A multinational study identified immune resilience as a critical factor influencing life span, HIV/AIDS, flu, sepsis mortality, recurrent skin cancer, and COVID-19 mortality. Individuals with optimal levels of immune resilience were more likely to resist infections and recover from inflammatory stressors.
A Johns Hopkins Medicine-led team identified protein fragments that stimulate the immune system to recognize and attack HIV. The study's technique, called reductionist cell-free antigen processing, replicates the complex events in the human immune system, enabling the identification of immunodominant epitopes.
Researchers from Oregon Health & Science University have discovered how stem cell transplantation can kill the virus that causes AIDS. The study, published in the journal Immunity, reveals that two circumstances must co-exist for a cure to occur and documents the order in which HIV is cleared from the body.
Researchers at the Center for One Health Research have found that antiviral drugs can make antifungals work again by blocking efflux pumps in Candida auris. This approach may be a key treatment strategy against the deadly fungal pathogen, which has a 60% mortality rate.
Scientists at Medical College of Georgia are investigating the impact of HIV treatment on bone and muscle aging. They found that common antiretroviral cocktails can accelerate aging by about a decade, leading to increased inflammation and oxidative stress in bone marrow stem cells.
Scientists at Temple University have developed a novel gene-editing strategy that disrupts the ability of HIV-1 virus to enter host cells by targeting a rare genetic disorder. This approach may offer another target for developing next-generation CRISPR technology for HIV elimination, while avoiding adverse effects on cell mortality.
A novel HIV restriction factor, Schlafen 12, has been identified as a key player in latent virus survival. This finding opens the possibility of designing new therapeutic strategies against HIV by blocking its antiviral functions.
Research from Boston Medical Center found that pulmonary tuberculosis enhances HIV antibody responses and increases the prevalence of antibody-resistant strains. This study has significant implications for HIV vaccines and antibody-based therapies, highlighting the need for novel strategies to generate broad and potent antibodies.
Researchers at Columbia University Irving Medical Center found that patients with well-controlled HIV responded similarly to those without HIV to tecovirimat treatment. Nearly all patients, regardless of HIV status, were pain-free by the end of the treatment regimen.
A cohort study of 196 people treated with tecovirimat found that HIV status did not impact treatment outcomes. Only 22% of participants experienced nonsevere adverse effects, and 4 serious adverse events occurred, with 3 being persons with HIV. The findings contradict previous uncertainty about HIV's role in mpox acquisition.
Researchers at Temple University and the University of Nebraska Medical Center developed a novel dual gene-editing approach that can effectively eliminate HIV infection. The therapy targets both HIV-1, the virus responsible for AIDS, and CCR5, a co-receptor that facilitates viral entry into cells.
Researchers uncover how HIV enters human bodies via dendritic cells using Siglec-1 membrane protein; formation of nanoclusters enhances capture, leading to virus compartment formation. Understanding this process can aid in developing effective treatments for HIV/AIDS.
A Danish study has validated a dried blood spot test that can detect HIV, hepatitis B, and hepatitis C from a single drop of blood. The test uses existing hospital equipment and is suitable for places where needle-based testing is not practical or feasible.